Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$84.00K$84.00K−52.5% vs Q1 2024 Net Income-$10.73M-$10.73MN/M vs Q1 2024 EPS Diluted-$0.35-$0.35N/M vs Q1 2024 Operating Income-$12,131,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Margins · derivedOperating margin-14441.7%−10488.0 pt vs Q1 2024
Net margin-12777.4%−8877.4 pt vs Q1 2024
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end